Your browser is no longer supported. Please, upgrade your browser.
ICPT Intercept Pharmaceuticals, Inc. daily Stock Chart
ICPT [NASD]
Intercept Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-10.36 Insider Own14.50% Shs Outstand32.96M Perf Week-15.85%
Market Cap964.56M Forward P/E- EPS next Y-7.48 Insider Trans-56.85% Shs Float27.80M Perf Month-26.31%
Income-339.30M PEG- EPS next Q-1.93 Inst Own84.70% Short Float23.09% Perf Quarter-36.85%
Sales283.40M P/S3.40 EPS this Y-0.20% Inst Trans1.25% Short Ratio8.51 Perf Half Y-66.21%
Book/sh-2.39 P/B- EPS next Y11.60% ROA-47.50% Target Price- Perf Year-57.16%
Cash/sh16.24 P/C1.80 EPS next 5Y-8.89% ROE- 52W Range28.40 - 125.00 Perf YTD-76.36%
Dividend- P/FCF- EPS past 5Y4.40% ROI-53.50% 52W High-76.56% Beta1.69
Dividend %- Quick Ratio3.70 Sales past 5Y170.50% Gross Margin98.00% 52W Low3.17% ATR2.02
Employees583 Current Ratio3.70 Sales Q/Q16.40% Oper. Margin- RSI (14)23.39 Volatility7.50% 5.60%
OptionableYes Debt/Eq- EPS Q/Q15.80% Profit Margin- Rel Volume0.98 Prev Close29.25
ShortableYes LT Debt/Eq- EarningsAug 10 BMO Payout- Avg Volume754.41K Price29.30
Recom2.60 SMA20-20.76% SMA50-30.53% SMA200-56.18% Volume741,758 Change0.17%
Jul-31-20Initiated Piper Sandler Overweight $82
Jul-21-20Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-30-20Upgrade Citigroup Neutral → Buy
Jun-30-20Downgrade UBS Buy → Neutral $135 → $57
Jun-30-20Downgrade Robert W. Baird Outperform → Neutral $52
Jun-30-20Downgrade Credit Suisse Outperform → Neutral $137 → $59
Jun-30-20Downgrade Cowen Outperform → Market Perform $47
Jun-30-20Downgrade Cantor Fitzgerald Overweight → Neutral
Jun-29-20Downgrade Wells Fargo Overweight → Equal Weight
Jun-29-20Downgrade RBC Capital Mkts Outperform → Sector Perform $117 → $55
Jun-29-20Downgrade Oppenheimer Outperform → Perform
Jun-29-20Downgrade Goldman Buy → Neutral $150 → $60
Jun-29-20Downgrade Canaccord Genuity Buy → Hold
Jun-29-20Downgrade BMO Capital Markets Outperform → Market Perform $107 → $52
Jun-25-20Initiated H.C. Wainwright Neutral $92
Jun-05-20Initiated BMO Capital Markets Outperform $107
May-22-20Downgrade Raymond James Strong Buy → Outperform $145 → $115
May-12-20Downgrade Citigroup Buy → Neutral
Apr-02-20Initiated Chardan Capital Markets Buy $145
Mar-05-20Resumed BofA/Merrill Neutral $111
Oct-23-20 09:50PM  
07:00PM  
12:30PM  
Oct-22-20 03:25PM  
12:25PM  
Oct-21-20 08:28PM  
Oct-14-20 08:38PM  
Oct-06-20 09:27PM  
Sep-13-20 08:08AM  
Sep-10-20 06:34PM  
Sep-09-20 11:30AM  
Sep-03-20 09:34AM  
08:00AM  
Sep-02-20 11:20AM  
08:19AM  
Sep-01-20 02:42PM  
Aug-28-20 12:45PM  
Aug-27-20 08:00AM  
Aug-21-20 08:00AM  
Aug-11-20 09:57AM  
08:41AM  
08:20AM  
06:04AM  
Aug-10-20 04:30PM  
08:25AM  
07:26AM  
07:00AM  
Aug-07-20 08:32AM  
Aug-04-20 11:34AM  
Aug-03-20 08:07AM  
Jul-29-20 12:33PM  
Jul-08-20 10:13AM  
Jul-02-20 02:25PM  
11:27AM  
Jul-01-20 06:55PM  
09:43AM  
07:02AM  
Jun-30-20 09:06PM  
10:29AM  
09:35AM  
Jun-29-20 06:00PM  
04:05PM  
04:00PM  
12:55PM  
11:25AM  
08:47AM  
07:40AM  
07:24AM  
07:00AM  
06:24AM  
Jun-25-20 10:10AM  
Jun-23-20 08:19PM  
Jun-17-20 01:15PM  
07:25AM  
Jun-16-20 03:41PM  
Jun-15-20 05:19PM  
Jun-12-20 03:51PM  
Jun-11-20 10:30AM  
Jun-10-20 11:30AM  
Jun-08-20 05:49PM  
Jun-05-20 09:56AM  
Jun-03-20 03:55PM  
12:35PM  
Jun-01-20 06:09PM  
06:06AM  
May-27-20 12:50PM  
10:08AM  
May-26-20 01:19PM  
May-22-20 04:17PM  
03:00PM  
11:54AM  
08:00AM  
05:51AM  
May-16-20 08:01AM  
May-14-20 05:31PM  
May-12-20 10:12AM  
May-11-20 06:00PM  
05:52PM  
09:55AM  
09:25AM  
09:08AM  
07:00AM  
May-06-20 08:30AM  
May-04-20 06:06AM  
May-03-20 10:55AM  
Apr-27-20 08:00AM  
Apr-01-20 09:04AM  
Mar-30-20 06:06PM  
Mar-29-20 11:49AM  
Mar-28-20 09:23PM  
Mar-26-20 04:24PM  
11:30AM  
08:00AM  
Mar-10-20 03:16PM  
11:53AM  
Mar-07-20 12:26AM  
Feb-28-20 08:00AM  
Feb-27-20 08:32AM  
Feb-26-20 10:14AM  
Feb-25-20 08:25AM  
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. It has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China; and Aralez Pharmaceuticals Canada Inc to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Campagna JasonChief Medical OfficerAug 18Sale47.441,19256,5438,778Aug 20 07:00 PM
Fundaro PaoloDirectorAug 17Sale47.071,362,40064,123,0994,000,000Aug 17 08:06 PM
Micheli Francesco10% OwnerAug 17Sale47.071,362,40064,123,0994,000,000Aug 17 08:10 PM
Genextra S.p.A.10% OwnerAug 17Sale47.071,362,40064,123,0994,000,000Aug 17 08:13 PM
Genextra S.p.A.10% OwnerAug 14Sale50.5554,6002,760,1125,362,400Aug 17 08:13 PM
Micheli Francesco10% OwnerAug 14Sale50.5554,6002,760,1125,362,400Aug 17 08:10 PM
Fundaro PaoloDirectorAug 14Sale50.5554,6002,760,1125,362,400Aug 17 08:06 PM
Fundaro PaoloDirectorAug 13Sale52.6083,0004,365,4515,417,000Aug 17 08:06 PM
Micheli Francesco10% OwnerAug 13Sale52.6083,0004,365,4515,417,000Aug 17 08:10 PM
Genextra S.p.A.10% OwnerAug 13Sale52.6083,0004,365,4515,417,000Aug 17 08:13 PM
Fundaro PaoloDirectorMay 13Sale84.60595,57850,385,8995,500,000May 15 05:19 PM
Micheli Francesco10% OwnerMay 13Sale84.60595,57850,385,8995,500,000May 15 04:55 PM
Genextra S.p.A.10% OwnerMay 13Sale84.60595,57850,385,8995,500,000May 15 04:46 PM
Weyer ChristianEVP, Research & DevelopmentApr 27Sale85.9518115,55717,140Apr 29 07:00 PM
Ford David AChief Human Resources OfficerApr 09Sale70.00584,06013,882Apr 10 07:00 PM
Weyer ChristianEVP, Research & DevelopmentFeb 27Sale87.621139,90117,367Feb 28 07:00 PM
Weyer ChristianEVP, Research & DevelopmentJan 27Sale94.0472367,99117,837Jan 27 07:01 PM
Campagna JasonChief Medical OfficerJan 07Sale113.0273282,7316,303Jan 08 07:00 PM
Pruzanski MarkPresident & CEODec 31Option Exercise21.501002,150469,226Jan 03 07:00 PM
Cawkwell GailSVP, Med Affairs, Safety & PVDec 31Option Exercise54.6326214,31318,984Jan 03 07:00 PM
Pruzanski MarkPresident & CEODec 31Sale125.0010012,500469,126Jan 03 07:00 PM
Cawkwell GailSVP, Med Affairs, Safety & PVDec 31Sale125.0026232,75018,722Jan 03 07:00 PM
Weyer ChristianEVP, Research & DevelopmentDec 27Option Exercise59.0847027,76615,759Dec 30 07:01 PM
Weyer ChristianEVP, Research & DevelopmentDec 27Sale123.241,581194,84214,178Dec 30 07:01 PM
Cawkwell GailSVP, Med Affairs, Safety & PVDec 26Option Exercise54.63542,95018,776Dec 30 07:00 PM
Pruzanski MarkPresident & CEODec 26Option Exercise21.504178,966469,543Dec 30 07:00 PM
Cawkwell GailSVP, Med Affairs, Safety & PVDec 26Sale125.00546,75018,722Dec 30 07:00 PM
Pruzanski MarkPresident & CEODec 26Sale125.0041752,125469,126Dec 30 07:00 PM
Campagna JasonChief Medical OfficerDec 19Sale119.4515418,3957,444Dec 20 07:00 PM
Cawkwell GailSVP, Med Affairs, Safety & PVDec 03Option Exercise54.63804,37018,722Dec 05 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 27Option Exercise59.1092754,78416,686Dec 02 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 27Sale101.651,040105,71615,646Dec 02 07:00 PM
Pruzanski MarkPresident & CEONov 26Option Exercise14.3035,437506,769504,563Nov 27 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 26Option Exercise59.114,373258,49120,132Nov 27 07:00 PM
Pruzanski MarkPresident & CEONov 26Sale100.0035,4373,543,700469,126Nov 27 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 26Sale100.004,373437,30015,759Nov 27 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 25Option Exercise59.101,855109,62817,614Nov 27 07:00 PM
Pruzanski MarkPresident & CEONov 25Option Exercise8.6714,563126,213483,689Nov 27 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 25Sale100.001,855185,50015,759Nov 27 07:00 PM
Pruzanski MarkPresident & CEONov 25Sale100.0014,5631,456,300469,126Nov 27 07:00 PM
Sullivan Ryan TGeneral Counsel and SecretaryNov 19Option Exercise53.418,325444,63834,043Nov 19 07:00 PM
Sullivan Ryan TGeneral Counsel and SecretaryNov 19Sale85.0012,1541,033,09021,889Nov 19 07:00 PM
Weyer ChristianEVP, Research & DevelopmentNov 19Sale85.001,550131,75015,759Nov 19 07:01 PM
Sullivan Ryan TGeneral Counsel and SecretaryNov 13Option Exercise53.4150026,70526,929Nov 15 07:02 PM
Weyer ChristianEVP, Research & DevelopmentNov 13Sale85.0094680,41017,309Nov 15 07:01 PM
Sullivan Ryan TGeneral Counsel and SecretaryNov 13Sale85.0050042,50026,429Nov 15 07:02 PM
Bright LisaPresident, InternationalOct 29Sale75.0059544,62518,732Oct 31 07:00 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.